SNY - Sanofi

Sanofi (SNY) Gains But Lags Market: What You Should Know

Sanofi (SNY) closed at $51.01 in the latest trading session, marking a +1.09% move from the prior day.

• 
  Align Technology (ALGN) Outpaces Stock Market Gains: What You Should Know

  Zacks
• 
  Qualcomm (QCOM) Stock Sinks As Market Gains: What You Should Know

  Zacks

Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies

FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge

Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge are included in this Analyst Blog.

Top Stock Reports for FEMSA, NextEra Energy & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).

Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal

Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.

Was This $3 Billion Deal a Wise Move for Sanofi?

The French drugmaker appears to have meaningfully improved its portfolio with the acquisition.

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

2 Bear Market Defying Stocks to Buy in May

This group of companies includes Sanofi (NASDAQ: SNY) and Axsome Therapeutics (NASDAQ: AXSM). France-based Sanofi is a biotech giant with a diversified portfolio of medicines and vaccines, although it is perhaps best known for being one of the leaders in the insulin market. The company grabbed headlines in this space earlier this year when it decided to cut the price of its top-prescribed insulin product, Lantus, by 78% and limit out-of-pocket costs to $35.

Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.

Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.

SNY or LLY: Which Is the Better Value Stock Right Now?

SNY vs. LLY: Which Stock Is the Better Value Option?

Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?

Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.

Sanofi (SNY) Q1 2023 Earnings Call Transcript

SNY earnings call for the period ending March 31, 2023.

Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised

Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.

Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong

Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.

Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.

Customized Treatments in Modern Medicine: Hear from Thirty Madison President and CFO Live from the NYSE Floor

IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with senior management from Thirty Madison . The in-person interview featured President Michelle Carnahan and […]

Is a Surprise Coming for Sanofi (SNY) This Earnings Season?

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AstraZeneca (AZN) to Report Q1 Earnings: What's in the Cards?

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates

We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.

Sanofi (SNY) is a Great Momentum Stock: Should You Buy?

Does Sanofi (SNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Sanofi (SNY) Stock Moves -0.45%: What You Should Know

In the latest trading session, Sanofi (SNY) closed at $55.47, marking a -0.45% move from the previous day.

Zacks.com featured highlights include Unum, Graphic Packaging Holding, AutoNation and Sanofi

Unum, Graphic Packaging Holding, AutoNation and Sanofi are part of the Zacks Screen of the Week article.

Will Sanofi (SNY) Surpass Estimates This Earnings Season?

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent.

Zacks.com featured highlights include Unum Group, Sanofi, KB Home, PVH and Telefonica Brasil

Unum Group, Sanofi, KB Home, PVH and Telefonica Brasil are part of the Zacks Screen of the Week article.